%0 Journal Article %A Qi Liu %A Shilei Zhao %A Yali Hou %A Sicheng Ye %A Tong Sha %A Yankai Su %A Wenming Zhao %A Yiming Bao %A Yongbiao Xue %A Hua Chen %T Ongoing natural selection drives the evolution of SARS-CoV-2 genomes %D 2020 %R 10.1101/2020.09.07.20189860 %J medRxiv %P 2020.09.07.20189860 %X SARS-CoV-2 is a new RNA virus affecting humans and spreads extensively through world populations since its first outbreak in late December, 2019. Whether the transmissibility and pathogenicity of SARS-CoV-2 is actively evolving, and driven by adaptation to the new host and environments is still unknown. Understanding the evolutionary mechanism underlying epidemiological and pathological characteristics of COVID-19 is essential for predicting the epidemic trend, and providing guidance for disease control and treatments. Interrogating 22,078 SARS-CoV-2 genome sequences of 84 countries, we demonstrate with convincing evidence that (i) SARS-CoV-2 genomes are overall conserved under purifying selection. (ii) Ongoing positive selection is actively driving the evolution of specific genes. Notably, genes related to coronavirus infection and host immune system defense are under adaptive evolution while genes related to viral RNA replication, transcription and translation are under purifying selection. A spatial and temporal landscape of 54 critical mutants is constructed based on their divergence among viral haplotype clusters, of which multiple mutants potentially conferring viral transmissibility, infectivity and virulence of SARS-CoV-2 are highlighted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the National Key R&D Program of China (Grant No. 2020YFC0847000, 2018YFC1406902, and 2018YFC0910402) and the Natural Science Foundation of China (Grant No. 31571370, 91731302, and 91631106).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are public data. %U https://www.medrxiv.org/content/medrxiv/early/2020/09/09/2020.09.07.20189860.full.pdf